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large-sized prosthesis seems preferable. On the other
hand, aortic root enlargement may complicate an opera-
tion for aortic valve replacement.1,4-11 Furthermore,
patients with small annular size may be small individuals,
and the small valve size may be matched to their cardiac
output needs. In addition to this uncertainty with respect
to the small aortic root, there is also controversy about
valve size and efficiency in general. Both the use of stent-
less aortic valve prostheses and the use of aortic
root–enlarging procedures are strategies based in large
part on the thesis that hemodynamic performance, and
thus valve size, favorably influence late outcome.12 The
purpose of this study was to ascertain the relation of pros-
thesis size to survival after aortic valve replacement.
Materials and methods
Patients. To obtain a relatively pure relation of prosthesis
size to survival, we identified adult patients (≥18 years of age)
operated on at The Cleveland Clinic Foundation from 1978
There is uncertainty as to the optimum management ofpatients with a small aortic anulus.1 Small aortic pros-
theses may leave higher residual pressure gradients across
the valve and are associated with less rapid and less com-
plete regression of left ventricular hypertrophy.2,3 Thus a
Objective: We sought to determine whether aortic prosthesis size adversely
influences survival after aortic valve replacement. 
Methods: A total of 892 adults receiving a mechanical (n = 346), pericardial
(n = 463), or allograft (n = 83) valve for aortic stenosis were observed for up
to 20 years (mean, 5.0 ± 3.9 years) after primary isolated aortic valve
replacement. We used multivariable propensity scores to adjust for valve
selection factors, multivariable hazard function analyses to identify risk fac-
tors for all-cause mortality, and bootstrap resampling to quantify the relia-
bility of the results. 
Results: Twenty-five percent of patients had indexed internal orifice areas of
less than 1.5 cm2/m2 and more than 2 SDs (Z-value) below predicted normal
aortic valve size. Mechanical valve orifices were smaller (1.3 ± 0.29 cm2/m2,
Z = –2.2 ± 1.16) than pericardial (1.9 ± 0.36 cm2/m2, Z = –0.40 ± 1.01) or
allograft valves (2.1 ± 0.50, Z = 0.24 ± 1.17). The overall survival was 98%,
96%, 86%, 69%, and 49% at 30 days and 1, 5, 10, and 15 years postopera-
tively. Univariably, survival was weakly and inversely related to manufac-
turer valve size (P = .16) and internal orifice diameter (P = .2) but com-
pletely unrelated to indexed valve area (P = .6) or Z-value (P = .8). These,
and univariable differences among valve types (P = .004), were accounted
for by different prevalences in patient risk factors and not by valve size or
type per se. Bootstrap resampling indicated that these findings had a less
than 15% chance of being incorrect. 
Conclusions: Survival after aortic valve replacement is strongly related to
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AORTIC VALVE REPLACEMENT: IS VALVE SIZE IMPORTANT?
through 1996 with (1) aortic stenosis (with or without regur-
gitation); (2) no concomitant procedures, such as coronary
artery bypass grafting; (3) no previous cardiac surgery; and
(4) one of three different categories of devices with different
expected orifice sizes with respect to the anulus. Through the
Cardiovascular Information Registry (CVIR), a prospective
ongoing registry of surgical and cardiologic procedures, we
identified 892 patients with aortic stenosis who had under-
gone primary isolated aortic valve replacement with either (1)
a mechanical prosthesis (St Jude Medical, standard, A101, n
= 346; St Jude Medical, Inc, St Paul, Minn), (2) a bovine
pericardial valve (Carpentier-Edwards Perimount RSR 2800,
n = 463; Baxter Healthcare Corp, Edwards Division, Santa
Ana, Calif), or (3) a cryopreserved allograft (CryoLife, n =
83; CryoLife, Inc, Kennesaw, Ga).
Preoperative symptoms were classified according to New
York Heart Association (NYHA) criteria. Patients underwent
preoperative left heart catheterization with coronary arteriog-
raphy, echocardiography, or both. Left ventricular function
was evaluated by echocardiography and by the left ventricu-
logram, when available, and grouped by function as being
normal or as having mild, moderate, or severe impairment.
Other variables used in the data analyses were obtained from
the concurrently abstracted data in the CVIR (see Appendix I).
Prostheses. Prosthesis selection was according to surgeon
preference. The numbers of patients receiving each prosthe-
sis type and size are presented in Table I. The relation of pros-
thesis size to survival was investigated by using 4 different
expressions of prosthesis size. First, the manufacturer’s
labeled size (see Table I) is commonly used to express pros-
thesis size. However, this was the external sewing ring size in
the mechanical valve, the tissue mounting device (anulus)
size in the pericardial valve, and the internal diameter in the
allografts. Second, each manufacturer provided us with its
official documentation of internal valve orifice diameter
(Table I), and we used this measurement as a uniform valve
size expression across valve types, as suggested by Christakis
and colleagues.13 Third, we then calculated the indexed inter-
nal valve orifice area as the internal area divided by the body
surface area of the patient (in cm2/m2). Finally, the final
expression of valve size was the standardized internal valve
orifice size or Z-value based on body surface area. The Z-
value is the number of SDs the internal orifice size differs
from the predicted mean normal native aortic valve size on
the basis of the patient’s body surface area (Appendix II).14,15
The relation of labeled prosthesis size to patient character-
istics was investigated by using multiple linear regression with
the demographic and clinical variables listed in Appendix I.
Follow-up and end point. Patients were followed within
the CVIR at 2-year intervals. Attempts were made to contact
any patient for whom follow-up was not current by mail, tele-
phone calls, or both during the summer of 1998. In all,
patients were followed for 4415 patient-years. Mean follow-
up among survivors was 5.0 ± 3.9 years; 25% were followed
up for 2 years or less, and 25% were followed up for 6 years or
more, with a maximum of 20 years. Twenty-seven patients had
incomplete follow-up of less than 6 months’ duration (3%).
The end point for this study was death from any cause, with
time zero being the time of operation.
Data analysis
Adjustment for patient selection. Although the availability
of several different categories of valves (mechanical, pericar-
dial, and allografts) provided an opportunity to investigate a
wide range of internal valve orifice sizes, the kind of patients
receiving each were not the same (Table II), and the time
frame for the use of each prosthesis was not uniform
(Appendix Fig 1). To take into account these selection fac-
tors, the probability that a patient would receive one of the 3
types of valve was determined by logistic regression of each
pair of valves. For this so-called propensity score (the
propensity to receive one or another valve), demographic,
symptom and cardiac comorbidity, and noncardiac comorbid-
ity factors shown in Table II were entered into each analysis
irrespective of P values.16-18 Because the models incorporat-
ed identical variables, the sum of the conditional probabilities
predicted for receiving each valve add to 100%. The pair-
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Table I. Relation between labeled prosthesis size and
internal orifice diameter
Diameter (mm)
Internal External 
Labeled size orifice sewing ring N
St Jude Medical, 346
standard (A-101)
19 14.7 19 57
21 16.7 21 91
23 18.5 23 117
25 20.4 25 50
27 22.3 27 22
29 24.1 29 9
Carpentier-Edwards Perimount 463
RSR Pericardial (2800)
19 18 26 110
21 20 28 137
23 22 31 126
25 24 32 73
27 26 35 16
29 28 37 1
Allograft 83
17 17 — 1
18 18 — 1
19 19 — 3
20 20 — 5
21 21 — 9
22 22 — 23
23 23 — 18
24 24 — 9
25 25 — 4
26 26 — 5
27 27 — 3
29 29 — 1
33 33 — 1
Total 892
wise propensity scores in the format of logit units were incor-
porated into multivariable analyses of death as a way to
adjust for selection factors.
Effectiveness of risk adjustment. In multivariable analyses
of survival, we did not find the propensity scores to be impor-
tantly or significantly related to survival. To test whether the
factors related to survival thus already adjusted adequately
for differences, we generated a separate predicted survival
curve for each patient on the basis of his or her valves for risk
factors. These were then superimposed on stratified univari-
able life table estimates to ascertain the effectiveness of con-
ventional risk adjustment.19
Analysis of survival. Nonparametric estimates of survival
were obtained by the method of Kaplan and Meier.20 A para-
metric method was used to resolve the number of phases of
instantaneous risk of death (hazard function) and to estimate
its shaping parameters.21
Exploratory analyses of the variables in Appendix I included
correlation analysis, stratified life table analyses, and decile
risk analysis of ordinal and continuous variables to determine
the possible transformations of scale needed to properly cali-
brate the variables to survival.
The risk of small valve size might be prominent early after
the operation or it may be a long-term risk. For this reason,
we used a method that simultaneously but specifically inter-
rogated the early, constant, and late hazard phases after the
operation.21 The analyses used a directed technique of entry
of variables into the multivariable model.22 The P value cri-
terion for retention of variables in the final model was .05.
Reliability of the analysis. Because we were unable to iden-
tify an influence of prosthesis size on survival, we ascertained
the reliability of this finding by using bootstrap resampling.23
Patients were drawn at random from the 892 study members
with replacement. This was repeated to construct a new data
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Table II. Patient characteristics according to type of valve received
Pericardial Mechanical Allograft
Variable No. % of 463 No. % of 346 No. % of 83 P value
Demography
Women 226 49 159 46 26 31 .01
Age (y) 71 ± 9.1 60 ± 11.1 48 ± 9.2 <.0001
Body surface area (m2) 1.9 ± 0.25 1.9 ± 0.25 2.0 ± 0.22 .0002
Symptoms and cardiac 
comorbidity
NYHA class .14
I 82 18 65 19 24 29
II 277 60 201 58 47 57
III 75 16 62 18 10 12
IV 29 6 18 5 1 1
Not classified — — — — — 1
Left ventricular dysfunction .3
Normal 336 73 257 75 62 82
Mild 50 11 38 11 5 7
Moderate 51 11 30 9 9 11
Severe 23 5 16 5 0 0
Not classified 3 — 5 — 7 —
Known (and unbypassed) .009
coronary artery disease
None 396 86 315 92 71 99
One-system disease 47 10 22 6 1 1
Two-system disease 16 3 4 1 0 0
Three-system disease 1 0.2 0 0 0 0
Not classified 3 — 5 — 6 —
Family history of 72/249* 29 85/205 41 10/51 20 .002
coronary artery disease
Endocarditis 7 2 13 4 1 1 .09
Noncardiac comorbidity
Hypertension 247/440 56 132/346 44 23/78 29 .001
Peripheral vascular disease 80 17 38 11 1 1 .001
Diabetes 63/415 15 18/309 6 7/75 9 .001
Chronic lung disease 64 14 23 7 7 8 .004
Renal disease 20 4 4 1 1 1 .02
Means are presented with 1 SD. P values are based on χ2 statistics for categoric variables and the Kruskal-Wallis nonparametric test for continuous variables.
*In some instances, when information was unavailable, the data are presented as n/number known.
set of 892 observations, which could contain one or more
duplicates of patients. This random sampling process was
repeated 1000 times to create 1000 differently constituted
data sets. We then inquired how often smaller valve size
would be selected as a risk factor at a P value of less than .05
in each hazard phase adjusted for the other factors found by
parsimonious modeling and the propensity scores.24
The bootstrap variable selection process was carried out for
indexed internal valve orifice area overall and repeated with
the indexed areas for the individual valve types (as interaction
terms). This entire process was repeated by using the stan-
dardized internal orifice size (Z-value). Thus 4000 separate
data sets were actually used in these 4 investigations. Because
of the small number of events in the early hazard phase, this
investigation was only conducted for the constant and late
hazard phases.
Results
Prosthesis size. The frequency of use of prostheses
of varying labeled and internal orifice size are shown in
Table I. The complete spectrum of internal orifice area
indexed to body surface area and its relation to the type
of valve is shown in Fig 1. Only 7 patients received
valves with indexed internal orifice areas below 0.85
cm2/m2. Mechanical prostheses had the smallest orifice
size (1.3 ± 0.29 cm2/m2, Z = –2.2 ± 1.16), and allo-
grafts had the largest in relation to body size (2.1 ± 0.50
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Fig 1. Cumulative distribution of prosthesis internal orifice
area indexed to body surface area. For orientation, the valve
size value along the horizontal axis corresponding to 50 along
the vertical axis is the median size; those at 25% and 75% are
the quartile values. A value of effective orifice size, which
will be smaller than these full-orifice sizes, below 0.85
cm2/m2 is considered to constitute patient-prosthesis mis-
match. A, Overall distribution; B, distribution stratified by
type of aortic valve prosthesis.
A
B
Fig 2. Cumulative distribution of prosthesis internal orifice
size standardized to body surface area according to the Z-
value. The Z-value represents the number of SDs the internal
orifice size departs from the mean normal native aortic valve
for a given body surface area. Normal native valve sizes are
generally considered to be those constrained within the 95%
confidence limits of normal values, corresponding to Z-val-
ues of –2 and +2. A, Overall distribution; B, distribution strat-
ified by type of aortic valve prosthesis.
cm2/m2, Z = 0.24 ± 1.17), with pericardial valves being
intermediate between the 2 (1.9 ± 0.36 cm2/m2, Z =
–0.40 ± 1.01). A quarter of the patients, mostly those
receiving a mechanical prosthesis, had internal valve
orifice sizes more than 2 SDs below normal native aor-
tic anulus size (Fig 2).
Patients receiving small-sized prostheses differed in
many respects from those receiving larger manufactur-
er’s label–sized valves (Table III). For example,
patients receiving size 19 or smaller prostheses were
more likely to be women, smaller in size, more likely
to have hypertension and peripheral vascular disease,
more likely to receive a pericardial valve, and less like-
ly to have left ventricular dysfunction.
By using multiple regression, the factors associat-
ed with manufacturer-labeled valve size were female
sex (–2.2 ± 0.141 mm smaller, P < .0001), body size
(1.91 ± 0.29 mm/m2 increase, P < .0001), left ven-
tricular dysfunction (0.197 ± 0.072 mm per grade
increase [0-3], P = .006), and age (younger: –1.06 ±
0.23·[age/50]2, P < .0001; older: –1.38 ± 0.67·[50/age],
P = .04).
Survival. The overall survival was 98%, 96%, 86%,
69%, and 49% at 30 days and 1, 5, 10, 15 years, respec-
tively (Fig 3). There were only 13 hospital deaths
(1.5%), precluding any meaningful examination of
early risk factors. Thus we focused on deaths across
time from the time of operation. The instantaneous risk
of death (hazard function) was highest immediately
after valve replacement but fell rapidly to its lowest
level and gradually rose after about 3 months. This pat-
tern of risk and the methods of analysis used allowed us
to focus on the influence of valve size at various time
intervals after operation.
Risk factors for death included older age, smaller
body size, endocarditis, family history of ischemic
heart disease, chronic lung disease, and chronic renal
disease (Table IV). Only small body size was identified
in the early hazard phase, and the others were distrib-
uted between constant and late hazard phases. No valve
type or expression of valve size was identified as a risk
factor.
Survival by valve type and size. By using univari-
able stratified life table analysis, differences in survival
among patients with different valve types were appar-
ent (P = .004), as shown in Fig 4. However, these dif-
ferences were accounted for by the patient’s risk fac-
tors, as demonstrated by the smooth curves in the
figure. These curves represent the risk-adjusted, indi-
vidual patient predictions on the basis of the multivari-
able analysis and averaged within valve types.
When the patients are stratified by labeled valve size,
smaller valves were associated with somewhat greater
risk (P = .16; Fig 5, A), but this difference was account-
ed for well by the differences in patient characteristics
that influenced survival (smooth curves in the figure).
Stratification by indexed internal orifice area rather
than labeled size inverts this relation (Fig 5, B).
Although not a statistically significant association (P =
.6), the small differences were well accounted for by
differences in prevalence of risk factors. These same
findings were true of internal orifice size standardized
to predicted normal native aortic valve size (P = .8; Fig
5, C). Thus all differences related to prosthesis type and
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Table III. Comparison of characteristics of patients receiving small (19 mm or less labeled size) and larger
(greater than 19 mm) prostheses
≤19 mm >19 mm
Variable No. % of 172 No. % of 720 P value
Women 161 94 250 35 <.001
Age (y) 69 ± 11.5 63 ± 12.3 <.0001
Body surface area (m2) 1.7 ± 0.21 2.0 ± 0.23 <.0001
NYHA class III-IV 37 22 158/719* 22 .9
Moderate or severe left ventricular 14/171 8 115/706 16 .007
dysfunction
Diabetes 18/155 12 70/644 11 .8
Peripheral vascular disease 31 18 88 12 .04
Hypertension 95/164 58 307/651 47 .01
Type of valve <.001
Mechanical 57 33 289 40 .09
Pericardial 110 64 353 49 <.001
Allograft 5 3 78 11 <.001
Means are presented with 1 SD. P values are based on χ2 statistics for categoric variables and the Kruskal-Wallis nonparametric test for continuous variables.
*In some instances, when information was unavailable, the data are presented as n/number known.
various expressions of valve size were well accounted
for by differences in prevalence of risk factors.
Table V, in which valve type and indexed internal
valve area were forced into the multivariable model,
demonstrates little association of these factors with sur-
vival. The same was true of the Z-value (Table VI).
The reliability of our inference that smaller valve size
is not associated adversely with survival was assessed
by bootstrap resampling (Table VII). This analysis
demonstrates that in studies of this size, less than 15%
will demonstrate an effect of small valve size on sur-
vival with a P value of less than .05. In the phase
important in the long term, this was reduced to less than
a 4% chance.
Discussion
Study strengths. In this study we have examined the
question of the influence on survival of aortic valve
size in a relatively pure group of patients that empha-
sizes small valve size (aortic stenosis). It is a relatively
large study, and the variables examined were collected
concurrently with the surgery into a registry. Follow-up
has been systematic. We have used all-cause death as
our end point because it is unequivocal and devoid of
subjective interpretation.
We have used modern sophisticated methods to inter-
pret the data in the face of nonuniform prosthesis selec-
tion and the nonrandomized nature of the study. We
have then tested the reliability of our inferences by
using computer-intensive sampling methodology.
Study limitations. The patients represent a single
institution’s experience and therefore may not be rep-
resentative of other venues. This is not a randomized
study and is retrospective, leaving the possibility that
selection bias might cause differences in patient groups
that might influence survival but are not accounted for,
even with the extensive multivariable analyses con-
ducted. Furthermore, this study does not examine all
outcomes but only survival. For patients undergoing
aortic valve replacement, meaningful survival data can
only be obtained from studies with large patient num-
bers. It is quite difficult to examine indices of left ven-
tricular mass regression over time and subtleties of late
symptom status for this large number of patients fol-
lowed for these postoperative intervals.
Importantly, the study is limited to patients with at
most moderate patient-prosthesis mismatch25 because
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Fig 3. Overall survival. A, Nonparametric (Kaplan-Meier)
and parametric estimates of overall survival. The circles are
the nonparametric estimates. The vertical bars are confidence
limits, equivalent to 1 SE. The numbers of patients remaining
at 2-year intervals are shown in parentheses. The smooth line
is the parametric survival estimate, and the dashed lines are
its confidence limits equivalent to 1 SE. B, Instantaneous risk
of death (hazard function).
Fig 4. Survival with patients stratified by type of prosthesis.
The smooth curves are derived from the risk factor analysis
(Table IV) that does not include valve type, demonstrating
that the differences are accounted for by differing prevalences
of risk factors (see the “Methods” section).
no deliberate attempt was made to use an undersized
prosthesis. Nevertheless, some 25% of patients had
moderate mismatch.
The patients were not randomized with respect to
either valve type or valve size. Indeed, deliberate selec-
tion of specific valve types for different patients is gen-
erally accepted in this mature era of valve replacement.
We used 3 valve types to examine a wide spectrum of
internal orifice sizes, even though this introduced a
possible confounding variable. We addressed this by
use of propensity scores to account for this selection.
Of course, we were unable to take into account
unrecorded selection factors. The fact that in no
instances were the propensity scores associated with
survival indicates that the factors in the multivariable
analysis adjusted well for patient heterogeneity with
respect to valve type selection.
We have used actual (in vitro) valve dimensions, even
when normalized and standardized to body surface
area, rather than effective valve orifice area. The effec-
tive valve orifice area is a dynamic, and not static, mea-
surement that varies with temporal loading conditions
and flow. Thus it is a poor variable for the kinds of
comparison done in this study. Commonly, the labeled
valve size has been used in discussions of small pros-
theses. This size clearly refers to different measure-
ment points for each valve type. We have therefore
used a uniform measurement for comparisons: the
internal diameter of the prosthesis.
Finally, follow-up, although extending up to 20
years, averaged only 5 years. Thus the inferences apply
mainly to intermediate-term survival.
Valve size. Both the use of stentless aortic valve
prostheses and the use of aortic root–enlarging proce-
dures are strategies based in large part on the thesis that
favorable hemodynamics from a large and efficient
prosthetic orifice size will improve late outcomes after
aortic valve replacement.
In part, this logic is based on the exponential increase
in the transprosthetic pressure gradient as indexed effec-
tive orifice size decreases, particularly below about 1
cm2/m2.26,27 The magnitude of this gradient in a pulse
duplicator system may be 20 mm Hg at a cardiac index
of 4.5 L · min–1 · m–2 at an indexed effective orifice area
of 1.0 cm2/m2. Because prostheses are not perfectly effi-
cient in vivo, the effective orifice area is generally less
than the calculated internal orifice area used in our study.
Any component of left ventricular outflow obstruction
must be added to the transprosthetic pressure gradient.27
In part, this logic is based on the more rapid and com-
plete regression of left ventricular hypertrophy in the
first few years after aortic valve replacement, as
assessed by echocardiography.2,3,28 In part, it is also
because others have found a relation between manufac-
turer-labeled prosthesis size and overall time-related
survival.29 The magnitude of this relation appeared to
be modest and in part related to differences in mortali-
ty after the operations.
In the present study the consumption of space by
sewing rings and stents is reflected in the indexed ori-
fice area and standardized orifice size. However, we
were unable to demonstrate an adverse relation
between smaller valve size by any of the 4 different
expressions and intermediate-term survival. This is a
broad statement in the context of many older patients
requiring aortic valve replacement for aortic stenosis;
there may be individual patients for whom prosthesis
size may be important.
This leaves unexplained the differences in intermedi-
ate-term survival in the case-matched study of the
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Table IV. Risk factors for death after aortic valve replacement identified by multivariable analysis
Hazard phase
Early Constant Late
Incremental risk factors for death Coefficient ± SD P value Coefficient ± SD P value Coefficient ± SD P value
Demography
Older age — — 0.036 ± 0.0119 .002 0.13 ± 0.027 <.0001
Body surface area –3.3 ± 1.42 .02 — — — —
Cardiac comorbidity
Family history of ischemic heart disease — — — — 0.85 ± 0.36 .02
Preoperative endocarditis — — 1.61 ± 0.45 .0003 — —
Noncardiac comorbidity
History of smoking — — — — 0.93 ± 0.36 .01
Chronic obstructive pulmonary disease — — 0.86 ± 0.34 .01 — —
Chronic renal disease — — 2.4 ± 0.4 <.0001 — —
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Fig 5. Survival with patients stratified by various expressions of prosthesis size. The smooth curves are derived
from the multivariable analysis (Table IV), as described in Fig 4 and the “Methods” section. A, Stratification by
labeled valve size (in mL); B, stratification by indexed internal orifice area (in cm2/m2); and C, stratification by
standardized internal orifice size (Z-value).
Table V. Risk factors for death after aortic valve replacement with prosthesis type and size (expressed as valve area
per square meter) forced into the model
Hazard phase
Early Constant Late
Incremental risk factors for death Coefficient ± SD P value Coefficient ± SD P value Coefficient ± SD P value
Prosthesis
Pericardial — — –0.32 ± 1.1 .8 –0.52 ± 9.3 .9
Mechanical — — –0.23 ± 1.1 .8 –0.55 ± 6.0 .9
Indexed internal orifice area (cm2/m2) — — –0.26 ± 0.38 .5 –0.0024 ± 0.079 .9
Demography
Older age — — 0.04 ± 0.014 .004 0.14 ± 0.029 <.0001
Body surface area –3.4 ± 1.4 .02 — — — —
Cardiac comorbidity
Family history of coronary artery disease — — — — 0.86 ± 0.37 .02
Preoperative endocarditis — — 1.6 ± 0.46 .0008 — —
Noncardiac comorbidity
History of smoking — — — — 0.94 ± 0.43 .03
Chronic obstructive pulmonary disease — — 0.87 ± 0.36 .02 — —
Chronic renal disease — — 2.4 ± 0.41 <.0001 — —
Toronto stentless prosthesis compared with a stented
xenograft.12 One can question how well matched that
study was (eg, with more aortic regurgitation patients)
in the stented group. Aortic enlargement was also used
to allow larger stented valve sizes to be used, and this
increases the early risk of operation.4
This study has focused on survival. Survival is not
the only outcome after aortic valve replacement,
although it is the most important. There are situations
where the use of complex forms of aortic valve replace-
ment, such as aortic valve homografts, pulmonary
valve autotransplantation, aortic root–enlarging proce-
dures, and, perhaps, stentless heterograft valves, to
achieve a more efficient aortic valve substitute are indi-
cated by a desire for a high patient activity level. In
those situations we have usually used aortic valve
homografts or pulmonary valve autotransplantation.
However, on the basis of our study, despite the argu-
ments from logic, survival appears not to be adversely
affected by aortic prosthesis size, even down to moder-
ate patient-prosthesis mismatch. Thus except in select-
ed circumstances, doing an operation, such as aortic
root enlargement, that increases short-term risk to
achieve a better long-term survival is not supported by
these data.
We thank Maura Schnauffer and Lucinda Mitchin for the
preparation of this manuscript.
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Table VII. Percentage of 1000 bootstrap resamplings
in which smaller valve size appears with P values of
less than .05
Hazard phase
Variables available Early Constant Late 
for selection (%) (%) (%)
Overall assessment
Z-value 1.6 13.9 2.3
Valve area (cm2/m2) 0.9 11.2 1.8
Assessment of valve type 
and size (Z-value)
Pericardial — 8.7 2.0
Mechanical — 6.5 0.5
Allograft — 0.0 1.5
Assessment by valve type 
and size (area, cm2/m2)
Pericardial — 10.7 3.3
Mechanical — 3.7 0.7
Allograft — 0.0 0.4
Table VI. Risk factors for death after aortic valve replacement with prosthesis type and size expressed as the number
of SDs below the normal native aortic valve size (Z-value) forced into the model
Hazard phase
Early Constant Late
Incremental risk factors for death Coefficient ± SD P value Coefficient ± SD P value Coefficient ± SD P value
Prosthesis
Pericardial — — –0.4 ± 0.6 .5 0.77 ± 6.0 .9
Mechanical — — –0.36 ± 0.62 .6 0.9 ± 6.0 .9
Standardized internal orifice size (Z-value) — — –0.1 ± 0.12 .4 0.13 ± 0.027 .6
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Cardiac comorbidity
Family history of coronary artery disease — — — — 0.89 ± 0.38 .02
Preoperative endocarditis — — 1.6 ± 0.46 .0006 — —
Noncardiac comorbidity
History of smoking — — — — 0.98 ± 0.38 .009
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Chronic renal disease — — 2.4 ± 0.39 <.0001 — —
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Appendix I: Variables
The following variables were examined in multivariable
analyses:
Demography
Age (years)
Sex
Race
Body surface area (m2)
Body mass index (kg/m2)
Preoperative status
New York Heart Association functional class
Emergency surgery
Left ventricular function
History of myocardial infarction
Evidence of previous infarction by electrocardiography
Left ventricular dysfunction index (see the “Methods” section)
Other cardiac comorbidity
Family history of coronary artery disease
Extent of coronary system disease (1-3)
Presence of preoperative atrial fibrillation
Endocarditis
Noncardiac comorbidity
Smoking
Insulin-treated diabetes
Noninsulin-treated diabetes
Hypertension
Peripheral vascular disease
Chronic obstructive pulmonary disease
Renal disease
Blood urea nitrogen level
Valve surgery
Prosthesis type
Labeled prosthesis manufacturer size (mm)
Prosthesis internal orifice diameter (mm)
Indexed internal orifice area (cm2/m2 body surface area)
Standardized internal orifice size (Z-value)
Experience
Years since 1977 when operation took place
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Propensity score
Conditional probability of pericardial valve type (logit units)
Conditional probability of mechanical valve type (logit units)
Conditional probability of allograft valve type (logit units)
Appendix II: The standardized valve size
For a number of years, the quantitative expression of car-
diac structures has been expressed in terms of the number of
SDs a patient’s structure deviates from normal.14,15 Gen-
erally, the normal structure size has been based on a logarith-
mic relation between structure size and body surface area. A
standardized expression is particularly important in growing
babies and children but has not been used extensively for
adults. For this study, we used the following relation between
aortic anulus diameter and body surface area (BSA), where ln
is the natural logarithm:
ln[mean normal aortic anulus diameter (mm)] = 2.770403 +
0.482279 · ln[BSA]
We used this, and its SD, to derive the Z-value by using the
following formula:
Z-value = [ln(internal orifice diameter) – ln(mean normal
anulus diameter)]/0.09224
Discussion
Dr Friedrich W. Mohr (Leipzig, Germany). This is a
very important study that contributes to and stimulates the
discussion on patient prosthesis selection and mismatch in
aortic valve surgery. Especially in patients with a small
aortic anulus, sufficient postoperative effective orifice
areas are required for optimal recovery. I think every one of
us thought this was the primary goal. Your article is very
much in contrast to the current knowledge that all of us
have been trained to perform aortic valve surgery and to get
the least gradient in surgery possible to overcome left ven-
tricular hypertrophy.
For aortic valve replacement, the goal must be the achieve-
ment of optimal hemodynamics and regression of left ven-
tricular hypertrophy. We thought it could be reached by using
the largest possible prosthetic valves. In your study you could
demonstrate that an effective prosthetic valve orifice area that
is not less than 4 SDs from the native aortic anulus index is
as efficient, and I think this is an important result. However,
the literature demonstrates that especially in the early out-
come operative mortality rate is higher in patients receiving
very small aortic valves, and this is in contrast to your own
experience.
Dr Medalion, I would like to ask you 3 questions. Do you
think that, because this study was a nonrandomized trial and
prosthesis selection was to the surgeon’s taste, this statisti-
cal analysis is really able to finally answer this question?
You are well aware of other reports with high, early opera-
tive mortality rates with very small prostheses. On the basis
of your results, what do you think about stentless aortic
valves for patients with small aortic roots? The risk factor of
left ventricular hypertrophy and the measured mass of left
ventricular hypertrophy did not seem to be analyzed in your
study.
In randomized prospective trials of stented valves versus
stentless valves, as well as in Tirone David’s series and our
series, it is clear that earlier and rapid regression of left ven-
tricular hypertrophy occurs if you calculate this risk factor.
Do you have any data on that?
Finally, please give us your current strategy from The
Cleveland Clinic in patients with small aortic roots after you
reviewed your data? Are you advising us not to hesitate to
implant these small valves?
Dr Medalion. Thank you, Dr Mohr, for discussing the arti-
cle. I will try to answer all 3 questions.
The findings of this study were somewhat surprising to us.
We thought that there would be extremes of valve-patient mis-
match in which we would see a negative effect on survival,
and we used very extensive and advanced statistical analyses
in attempts to define a level of mismatch that was important.
However, we were unable to demonstrate this effect. There
are, however, a couple of important points to keep in mind. 
First, these operations were performed, in general, by sur-
geons with a bias in favor of larger valves, and therefore severe
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Appendix Fig 1. Valve usage across time.
valve-patient mismatches were uncommon. Second, the end
point of the study is survival. With this large number of patients
being followed up, it is impossible to test exercise capacity and
symptom status for them all. Valve size may be important for
patients for whom a high activity level is important. In our cur-
rent practice, we use aortic valve homografts, aortic root–
enlarging procedures, and pulmonary valve autotransplantation
for young patients with high activity level expectations. Thus
we believe there are some indications for complex aortic root
operations to achieve maximal valve efficiency.
However, the thought that no patient should ever receive a
size 19 or size 21 valve because that strategy will lead to an
increased risk of late death cannot be supported by these data.
For most patients, the in-hospital risk of aortic valve replace-
ment with standard prostheses is extremely low. Performing
more complex operations makes sense only if they do not
increase the risk of in-hospital mortality because the idea that
a moderate valve-patient mismatch will lead to a shortened
long-term survival is a concept that has no data to support it
at the present time.
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